Last reviewed · How we verify
Fluvirin(TIVf)
Fluvirin(TIVf) is a Inactivated influenza vaccine Biologic drug developed by Novartis. It is currently FDA-approved for Seasonal influenza prevention in adults and children ≥4 years of age. Also known as: Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived).
Fluvirin is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Fluvirin (TIVf) is a vaccine used to prevent influenza in humans. It is a trivalent subunit inactivated vaccine that has been studied for its immunogenicity, safety, and tolerability in healthy subjects aged 50 years and above.
At a glance
| Generic name | Fluvirin(TIVf) |
|---|---|
| Also known as | Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived) |
| Sponsor | Novartis |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fluvirin contains inactivated (killed) influenza virus particles or viral antigens from three seasonal flu strains (hence TIVf for trivalent inactivated vaccine, formulated). When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (primarily IgG) against the included influenza A and B strains. This allows the vaccinated individual to mount a rapid immune response upon exposure to circulating influenza viruses, reducing infection risk and disease severity.
Approved indications
- Seasonal influenza prevention in adults and children ≥4 years of age
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia (muscle pain)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects (PHASE3)
- Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above (PHASE3)
- Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age (PHASE3)
- Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above (PHASE4)
- Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above (PHASE3)
- Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluvirin(TIVf) CI brief — competitive landscape report
- Fluvirin(TIVf) updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Fluvirin(TIVf)
What is Fluvirin(TIVf)?
How does Fluvirin(TIVf) work?
What is Fluvirin(TIVf) used for?
Who makes Fluvirin(TIVf)?
Is Fluvirin(TIVf) also known as anything else?
What drug class is Fluvirin(TIVf) in?
What development phase is Fluvirin(TIVf) in?
What are the side effects of Fluvirin(TIVf)?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults and children ≥4 years of age
- Also known as: Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing